Phoenix PharmaLabs
Addressing the opioid crisis by developing potent, safe, non-addictive painkillers.
Analytics
Raised to Date: $0
Aggregate Commitments $
Netcapital
12/24/2020
02/22/2021
$10,000
$1,070,000
$99
Equity - Common
RegCF
Seed
$26,790,283
Weekly Commitments $
Active
01/20/2021
31
0%
0%
$0
Woods Cross, Utah
Healthcare & Pharmaceuticals
HealthTech
B2B2C
High
High
Phoenix PharmaLabs, with a post-money valuation of $26,790,283, is raising funds on NetCapital. The company is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. John Lawson, PH.D. and Lawrence Toll, PH.D. founded Phoenix PharmaLabs. The crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,070,000. Phoenix PharmaLabs lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$1,285,068 |
$66,654 |
COGS |
$0 |
$0 |
Tax |
$0 |
$100 |
| ||
| ||
Net Income |
$-477,945 |
$-939,817 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$761,206 |
$37,344 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$761,206 |
$37,344 |
Short-Term Debt |
$2,058,665 |
$1,964,449 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$2,058,665 |
$1,964,449 |
Summary of Crowdfunding Raises
Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
02/22/2021 | Netcapital | $26,790,283 | $0 | Equity - Common | Active | RegCF |
03/30/2019 | Netcapital | $23,136,335 | $1,102,553 | Equity - Common | Confirmed Closed | RegCF |
Other Deals

Millennial Fertility Co. on NetCapital
The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…

Biopact on Equifund CFP
Biopact has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…

Neurotez Inc. on NetCapital
Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected…